Chronotherapy in head and neck cancer: A systematic review and meta‐analysis

Mohammad Abusamak,Abdel‐Azez Abu‐Samak,Wenji Cai,Haider Al‐Waeli,Faez Saleh Al‐Hamed,Mohammad Al‐Tamimi,Malik Juweid,Akhilanand Chaurasia,Belinda Nicolau,Faleh Tamimi
DOI: https://doi.org/10.1002/ijc.35234
2024-11-09
International Journal of Cancer
Abstract:What's New? Adverse events are common after chemotherapy and radiotherapy. Chronotherapy, which tailors treatment to the circadian rhythm, aims to reduce the frequency of adverse events and improve treatment efficacy. Here, the authors conducted a systematic review of chrono‐chemotherapy and chrono‐radiotherapy in patients with head and neck cancer (HNC). Their analysis included 22 studies and 3366 patients. Patients who received chrono‐radiotherapy had fewer instances of oral mucositis than those who received evening radiotherapy, they found; patients who received chrono‐chemotherapy experienced lower overall toxicity and improved objective response rate than those who received nontime‐stipulated chemotherapy. Optimizing the timing of radiotherapy and chemotherapy tailored to the body's biological clock (i.e., chronotherapy) might improve treatment efficacy and reduce side effects. This systematic review evaluated the effect of chrono‐radiotherapy and chrono‐chemotherapy on treatment efficacy, toxicity and adverse events in head and neck cancer (HNC) patients from prospective and retrospective studies published between the date of database inception until March 2024. The primary outcome measures for chrono‐radiotherapy were treatment efficacy and incidence of grade ≥3 oral mucositis, and the main outcome measures for chrono‐chemotherapy were objective response rate (ORR) and overall toxicity and adverse events. Of 7349 records identified, 22 studies with 3366 patients were included (chrono‐radiotherapy = 9 and chrono‐chemotherapy = 13). HNC patients who underwent chrono‐radiotherapy had 31% less risk of developing severe oral mucositis (grade ≥3) compared to evening radiotherapy (risk ratio: 0.69, 95% CI: 0.53–0.90, p
oncology
What problem does this paper attempt to address?